Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1203-1208, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woodrum, D. L.
Right arrow Articles by Shamel, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woodrum, D. L.
Right arrow Articles by Shamel, L. B.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1997;43:1203-1208.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate-specific antigen

David L. Woodruma, Chester M. French, Timothy M. Hill, Steven J. Roman, Harold L. Slatore, Jennifer L. Shaffer, Lisa G. York, Kathy L. Eure, Kathleen G. Loveland, Gail H. Gasior, Paula C. Southwick and L. Blair Shamel

Department of Research and Development, Hybritech Inc., San Diego, CA 92196.
a Author for correspondence. Fax 619-536-8058; e-mail dlwoodrum{at}beckman.com

The analytical performance of the Tandem®-R free PSA assay available from Hybritech Inc. was evaluated. Comparison of recoveries of purified free (unbound) prostate-specific antigen (PSA) diluted in female serum in the Tandem-R free PSA assay and the Tandem-R (total) PSA assay demonstrated a link in calibration between the assays and an accurate determination of percent free PSA. The cross-reactivity of the assay to purified PSA–{alpha}1-antichymotrypsin was determined to be <1%. The minimum-detectable concentration was <0.05 µg/L. The within-run and between-day CVs were <=5% for samples with >0.3 µg/L free PSA. Dilution and recovery showed no significant deviations from linearity across the assay range. The assay was insensitive to interference from blood components. The Tandem-R free PSA kit was shown to be an accurate, precise, and reliable assay for the measurement of free PSA.


Key Words: indexing terms: tumor markers • prostate cancer




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. Khosravi, A. Diamandi, J. Mistry, and A. Scorilas
Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 694 - 699.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
A. Magklara, A. Scorilas, W. J. Catalona, and E. P. Diamandis
The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA
Clin. Chem., November 1, 1999; 45(11): 1960 - 1966.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. W. Chan, C. A. Kelley, T. L. Ratliff, D. D'Agostino, J. Ritchey, D. J. Lamb, J. Beck, N. Lott, M. H. Wener, P. Daum, et al.
Analytical and Clinical Performance Characteristics of Hybritech's Tandem-R free PSA Assay during a Large Multicenter Clinical Trial to Determine the Clinical Utility of Percentage of Free Prostate-specific Antigen
Clin. Chem., October 1, 1999; 45(10): 1863 - 1865.
[Full Text] [PDF]

Home page
 JAMAHome page
W. J. Catalona, A. W. Partin, K. M. Slawin, M. K. Brawer, R. C. Flanigan, A. Patel, J. P. Richie, J. B. deKernion, P. C. Walsh, P. T. Scardino, et al.
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
JAMA, May 20, 1998; 279(19): 1542 - 1547.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.